{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:17:30Z","timestamp":1764890250734,"version":"3.46.0"},"reference-count":52,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"unspecified","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011094","name":"Public Health Agency of Canada","doi-asserted-by":"publisher","award":["2021-HQ-000149"],"award-info":[{"award-number":["2021-HQ-000149"]}],"id":[{"id":"10.13039\/100011094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["181116"],"award-info":[{"award-number":["181116"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,7]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the association between rates of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection following home, community and work-related exposures, to assess real-world relative vaccine effectiveness, and to determine whether anti-receptor-binding domain (RBD) IgG levels were associated with the rates of subsequent infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Prospective cohort of 34 months\u2019 duration (February 2021 to December 2023).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Teachers and education workers working \u22658\u2009hours per week in the Canadian province of Ontario.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>3155 education workers were eligible for the risk factor analysis; 2977 for the serological analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measure<\/jats:title>\n                    <jats:p>Rate of SARS-CoV-2 infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>1909 SARS-CoV-2 infections were reported (0.93 per 1000 participant-days); the highest incidence occurred during the period dominated by the Omicron BA.2 variant (2.01 per 1000 participant-days). Rates of infection were significantly higher following the repeal of the mask mandate. Compared with participants without known contact with an infected person, those in close contact with infected adult or child household members (adjusted HR (aHR) 1.43; 95%\u2009CI 1.24 to 1.65 and 1.39; 95%\u2009CI 1.17 to 1.65, respectively), coworkers (aHR 1.28; 95%\u2009CI 1.10 to 1.50), or individuals from more than one setting (aHR 1.44; 95%\u2009CI 1.27 to 1.64) had higher rates of infection. Participants with three or more doses of vaccine were 79%\u201387%\u2009less likely to develop SARS-CoV-2 than participants who had two or fewer vaccine doses. Blood samples with anti-RBD antibody levels in the highest quintile (\u22655850 binding antibody unit\/mL) were associated with a lower rate of subsequent infection (aHR 0.40; 95%\u2009CI 0.23 to 0.72) compared with samples with RBD levels below the threshold of detection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Risk of SARS-CoV-2 infection in education workers occurred at home as well as the workplace, indicating the need to practise multiple intervention strategies whenever the potential for transmission of respiratory diseases is high. COVID-19 vaccines provided protection through December 2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-103843","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:01:20Z","timestamp":1761116480000},"page":"e103843","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["SARS-CoV-2 infection following home, community and work-related exposures: a prospective cohort of teachers and education workers in Ontario, Canada, 2021\u20132023"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7144-4827","authenticated-orcid":false,"given":"Brenda L","family":"Coleman","sequence":"first","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"},{"name":"Sinai Health, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Bondy","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailey","family":"Fischer","sequence":"additional","affiliation":[{"name":"Sinai Health, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"Gutmanis","sequence":"additional","affiliation":[{"name":"Sinai Health, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Veronica","family":"Zhu","sequence":"additional","affiliation":[{"name":"Sinai Health, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2347-970X","authenticated-orcid":false,"given":"Kanchan","family":"Kanchan","sequence":"additional","affiliation":[{"name":"Sinai Health, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon E","family":"Straus","sequence":"additional","affiliation":[{"name":"Unity Health Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kim","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory, Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Simon","sequence":"additional","affiliation":[{"name":"National Microbiology Laboratory, Winnipeg, Manitoba, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"McGeer","sequence":"additional","affiliation":[{"name":"University of Toronto, Toronto, Ontario, Canada"},{"name":"Sinai Health, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"2025120415075193000_15.10.e103843.1","doi-asserted-by":"crossref","DOI":"10.1186\/s12995-023-00371-9","article-title":"Differential Risk of SARS-CoV-2 Infection by Occupation: Evidence from the Virus Watch prospective cohort study in England and Wales","volume":"18","author":"Beale","year":"2023","journal-title":"J Occup Med Toxicol"},{"key":"2025120415075193000_15.10.e103843.2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajim.23665","article-title":"Prevalence of COVID\u201019 and Long COVID by Industry and Occupation: Behavioral Risk Factor Surveillance System 2022","volume":"68","author":"Silver","year":"2025","journal-title":"American J Industrial Med"},{"key":"2025120415075193000_15.10.e103843.3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1136\/bmjebm-2022-112085","article-title":"School closures during COVID-19: an overview of systematic reviews","volume":"28","author":"Hume","year":"2023","journal-title":"BMJ EBM"},{"key":"2025120415075193000_15.10.e103843.4","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00753-2"},{"key":"2025120415075193000_15.10.e103843.5","doi-asserted-by":"crossref","unstructured":"Wei J , Stoesser N , Matthews PC , et al . Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population. Nat Commun 2024;15. doi:10.1038\/s41467-024-44973-1","DOI":"10.1101\/2023.06.29.23292043"},{"key":"2025120415075193000_15.10.e103843.6","doi-asserted-by":"crossref","unstructured":"B\u00f8\u00e5s H , Storm ML , Tapia G , et al . Frequency and risk of SARS-CoV-2 reinfections in Norway: a nation-wide study, February 2020 to January 2022. BMC Public Health 2020;24. doi:10.1186\/s12889-024-17695-8","DOI":"10.1186\/s12889-024-17695-8"},{"key":"2025120415075193000_15.10.e103843.7","doi-asserted-by":"crossref","DOI":"10.34172\/jrhs.2024.161","article-title":"COVID-19 Vaccine Effectiveness of Booster Doses Against Delta and Omicron Variants Over Follow-up Times Using Longitudinal Meta-analysis","volume":"24","author":"Mostafavi","year":"2024","journal-title":"J Res Health Sci"},{"key":"2025120415075193000_15.10.e103843.8","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1093\/aje\/kwae142","article-title":"Prior infections and effectiveness of SARS-CoV-2 vaccine in test-negative studies: a systematic review and meta-analysis","volume":"193","author":"Tsang","year":"2024","journal-title":"Am J Epidemiol"},{"key":"2025120415075193000_15.10.e103843.9","unstructured":"World health organization . Correlates of Vaccine-Induced Protection: Methods and Implications. Geneva, CH: World Health Organization, 2013. Available: https:\/\/www.who.int\/publications\/i\/item\/WHO-IVB-13.01"},{"key":"2025120415075193000_15.10.e103843.10","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-22146-8","article-title":"Comparable diagnostic accuracy of SARS-CoV-2 Spike RBD and N-specific IgG tests to determine pre-vaccination nation-wide baseline seroprevalence in Mexico","volume":"12","author":"Mart\u00ednez-Barnetche","year":"2022","journal-title":"Sci Rep"},{"key":"2025120415075193000_15.10.e103843.11","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s15010-024-02189-x","article-title":"Protective role of SARS-CoV-2 anti-S IgG against breakthrough infections among European healthcare workers during pre and post-Omicron surge-ORCHESTRA project","volume":"52","author":"Spiteri","year":"2024","journal-title":"Infection"},{"key":"2025120415075193000_15.10.e103843.12","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29839","article-title":"Anti-Spike IgG antibodies as correlates of protection against SARS-CoV-2 infection in the pre-Omicron and Omicron era","volume":"96","author":"Seekircher","year":"2024","journal-title":"J Med Virol"},{"key":"2025120415075193000_15.10.e103843.13","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268825100101","article-title":"Risk factors for infection with SARS-CoV-2 in a cohort of Canadian healthcare workers: 2020-2023","volume":"153","author":"Coleman","year":"2025","journal-title":"Epidemiol Infect"},{"key":"2025120415075193000_15.10.e103843.14","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11061077","article-title":"Anti-SARS-CoV-2 IgG Antibody Response in Individuals Infected Post Complete Vaccination: A 6-Month Longitudinal Study in Healthcare Professionals","volume":"11","author":"Baratto","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"2025120415075193000_15.10.e103843.15","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11121835","article-title":"Long-Term Analyses of SARS-CoV-2 Humoral and T Cell Responses and Breakthrough SARS-CoV-2 Infections after Two Doses of BNT162b2 Followed by mRNA-1273 and Bivalent Omicron-Adapted BNT162b2 Vaccines: A Prospective Study over 2 Years in Non-Immunocompromised Individuals","volume":"11","author":"Erice","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"2025120415075193000_15.10.e103843.16","doi-asserted-by":"publisher","DOI":"10.17269\/s41997-022-00613-z"},{"key":"2025120415075193000_15.10.e103843.17","unstructured":"Public Health Ontario . COVID-19 vaccine uptake in Ontario: December 14, 2020 to April 17, 2021. Toronto, 2021. Available: https:\/\/www.publichealthontario.ca\/-\/media\/Documents\/nCoV\/Archives\/Vaccine-Uptake\/2021\/04\/covid-19-vaccine-uptake-report-2021-04-22.pdf"},{"key":"2025120415075193000_15.10.e103843.18","unstructured":"Public Health Agency of Canada . COVID-19 vaccination: doses administered. Government of Canada; 2024. Available: https:\/\/health-infobase.canada.ca\/covid-19\/vaccine-administration\/"},{"key":"2025120415075193000_15.10.e103843.19","unstructured":"Government of Canada . NACI rapid response: recommended use of astrazeneca COVID-19 vaccine in younger adults. 2021. Available: https:\/\/www.canada.ca\/en\/public-health\/services\/immunization\/national-advisory-committee-on-immunization-naci\/rapid-response-recommended-use-astrazeneca-covid-19-vaccine-younger-adults.html"},{"key":"2025120415075193000_15.10.e103843.20","unstructured":"Government of Ontario . Approach to reopening schools for the 2020-2021 school year. 2020. Available: https:\/\/www.ontario.ca\/page\/approach-reopening-schools-2020-2021-school-year#section-5"},{"key":"2025120415075193000_15.10.e103843.21","doi-asserted-by":"crossref","DOI":"10.1038\/s41597-023-02759-y","article-title":"Canadian Covid-19 pandemic public health mitigation measures at the province level","volume":"10","author":"Akanteva","year":"2023","journal-title":"Sci Data"},{"key":"2025120415075193000_15.10.e103843.22","unstructured":"Government of Ontario . Statement from Ontario\u2019s chief medical officer of health. 2022 Available: https:\/\/news.ontario.ca\/en\/statement\/1001732\/statement-from-ontarios-chief-medical-officer-of-health"},{"key":"2025120415075193000_15.10.e103843.23","unstructured":"SimpleSurvey . SimpleSurvey enterprise. Montreal, QC, 2021. Available: https:\/\/simplesurvey.com\/"},{"key":"2025120415075193000_15.10.e103843.24","unstructured":"World Health Organization . WHO international standard. first WHO international standard for anti-sars-cov-2 immunoglobulin (human). 2020. Available: https:\/\/nibsc.org\/documents\/ifu\/20-136.pdf"},{"key":"2025120415075193000_15.10.e103843.25","doi-asserted-by":"crossref","DOI":"10.1186\/s41256-022-00245-3","article-title":"Reinfection in patients with COVID-19: a systematic review","volume":"7","author":"Ren","year":"2022","journal-title":"Glob Health Res Policy"},{"key":"2025120415075193000_15.10.e103843.26","unstructured":"Public Health Agency of Canada . National microbiology laboratory. 2024. Available: https:\/\/www.canada.ca\/en\/public-health\/programs\/national-microbiology-laboratory.html"},{"key":"2025120415075193000_15.10.e103843.27","unstructured":"Ontario Health Data Science Branch . Ontario health data science branch. deaths involving covid-19 by fatality type. Government of Ontario; 2024. Available: https:\/\/data.ontario.ca\/dataset\/deaths-involving-covid-19-by-fatality-type"},{"key":"2025120415075193000_15.10.e103843.28","doi-asserted-by":"crossref","first-page":"110859","DOI":"10.1016\/j.clinbiochem.2024.110859","article-title":"Characterizing the SARS-CoV-2 antibody response and associations with patient factors: Serological profiling of participants enrolled in the GENCOV study","volume":"135","author":"Morgan","year":"2025","journal-title":"Clin Biochem"},{"key":"2025120415075193000_15.10.e103843.29","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12010036","article-title":"Predictors of Breakthrough SARS-CoV-2 Infection after Vaccination","volume":"12","author":"Walmsley","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"2025120415075193000_15.10.e103843.30","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyu222"},{"key":"2025120415075193000_15.10.e103843.31","doi-asserted-by":"crossref","DOI":"10.1093\/biomet\/68.2.373","article-title":"On the Regression Analysis of Multivariate Failure Time Data","volume":"68","author":"Prentice","year":"1981","journal-title":"Biometrika"},{"key":"2025120415075193000_15.10.e103843.32","unstructured":"StataCorp LLC . Stata survival analysis reference manual. College Station, TX; 2023. Available: www.stata.com\/manuals\/st.pdf"},{"key":"2025120415075193000_15.10.e103843.33","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1055\/s-0043-1766118","article-title":"Transmission and Risk Factors of COVID-19 among Health Care Workers","volume":"44","author":"Alghader","year":"2023","journal-title":"Semin Respir Crit Care Med"},{"key":"2025120415075193000_15.10.e103843.34","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1017\/ice.2022.108","article-title":"Transmission of severe acute respiratory coronavirus virus 2 (SARS-CoV-2) between hospital workers and members of their household: Nationwide, registry-based, cohort study from Norway","volume":"44","author":"Elgersma","year":"2023","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2025120415075193000_15.10.e103843.35","doi-asserted-by":"crossref","unstructured":"Coleman BL , Robertson N , Harrison R , et al . Risk Factors for Infection with SARS-CoV-2 in a Cohort of Canadian Healthcare Workers: 2020-2023.2025:30.","DOI":"10.1017\/S0950268825100101"},{"key":"2025120415075193000_15.10.e103843.36","doi-asserted-by":"crossref","first-page":"e814","DOI":"10.1016\/S2666-5247(22)00124-0","article-title":"Transmission of SARS-CoV-2 by children to contacts in schools and households: a prospective cohort and environmental sampling study in London","volume":"3","author":"Cordery","year":"2022","journal-title":"Lancet Microbe"},{"key":"2025120415075193000_15.10.e103843.37","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20210106"},{"key":"2025120415075193000_15.10.e103843.38","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00622-22","article-title":"Symptomatic and Asymptomatic Transmission of SARS-CoV-2 in K-12 Schools, British Columbia, Canada April to June 2021","volume":"10","author":"Choi","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2025120415075193000_15.10.e103843.39","doi-asserted-by":"crossref","unstructured":"Campeau L , Thistlethwaite F , Yao JA , et al . Transmission dynamics of SARS-CoV-2 in British Columbia\u2019s largest school district during the second half of the 2020-2021 school year. Can J Public Health 2022;113. doi:10.17269\/s41997-022-00659-z","DOI":"10.17269\/s41997-022-00659-z"},{"key":"2025120415075193000_15.10.e103843.40","doi-asserted-by":"crossref","unstructured":"Powers KA , Sullivan KM , Zadrozny SL , et al . North Carolina public school teachers\u2019 contact patterns and mask use within and outside of school during the prevaccine phase of the COVID-19 pandemic. Am J Infect Control 2022;50. doi:10.1016\/j.ajic.2021.12.020","DOI":"10.1016\/j.ajic.2021.12.020"},{"key":"2025120415075193000_15.10.e103843.41","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268821002077","article-title":"Surveillance of SARS-CoV-2 transmission in educational institutions, August to December 2020, Germany","volume":"149","author":"Schoeps","year":"2021","journal-title":"Epidemiol Infect"},{"key":"2025120415075193000_15.10.e103843.42","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(20)30882-3"},{"key":"2025120415075193000_15.10.e103843.43","doi-asserted-by":"crossref","first-page":"289","DOI":"10.15585\/mmwr.mm7008e4","article-title":"Clusters of SARS-CoV-2 Infection Among Elementary School Educators and Students in One School District \u2014 Georgia, December 2020\u2013January 2021","volume":"70","author":"Gold","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025120415075193000_15.10.e103843.44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211029"},{"key":"2025120415075193000_15.10.e103843.45","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2105\/AJPH.2022.307095","article-title":"School District Prevention Policies and Risk of COVID-19 Among In-Person K-12 Educators, Wisconsin, 2021","volume":"112","author":"DeJonge","year":"2022","journal-title":"Am J Public Health"},{"key":"2025120415075193000_15.10.e103843.46","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgae065","article-title":"Impact of community mask mandates on SARS-CoV-2 transmission in Ontario after adjustment for differential testing by age and sex","volume":"3","author":"Peng","year":"2024","journal-title":"PNAS Nexus"},{"key":"2025120415075193000_15.10.e103843.47","doi-asserted-by":"crossref","DOI":"10.2196\/42616","article-title":"The Impact of Mask Mandates on Face Mask Use During the COVID-19 Pandemic: Longitudinal Survey Study","volume":"9","author":"Binka","year":"2023","journal-title":"JMIR Public Health Surveill"},{"key":"2025120415075193000_15.10.e103843.48","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-022-02397-y","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis","volume":"20","author":"Zeng","year":"2022","journal-title":"BMC Med"},{"key":"2025120415075193000_15.10.e103843.49","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2024.100451","article-title":"Reported effectiveness of COVID-19 monovalent booster vaccines and hybrid immunity against mild and severe Omicron disease in adults: A systematic review and meta-regression analysis","volume":"17","author":"Nealon","year":"2024","journal-title":"Vaccine X"},{"key":"2025120415075193000_15.10.e103843.50","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.vaccine.2024.04.049","article-title":"A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants","volume":"42","author":"Song","year":"2024","journal-title":"Vaccine (Auckl)"},{"key":"2025120415075193000_15.10.e103843.51","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines12050494","article-title":"Serological Correlates of Protection Induced by COVID-19 Vaccination in the Working Age Population: A Systematic Review and Meta-Analysis","volume":"12","author":"Rahmani","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"2025120415075193000_15.10.e103843.52","unstructured":"Government of Canada . Interim guidance on the use of rapid antigen detection tests for the identification of sars-cov-2 infection. 2024. Available: https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/2019-novel-coronavirus-infection\/guidance-documents\/use-rapid-antigen-detection-tests.html"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-103843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T23:13:16Z","timestamp":1764889996000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-103843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":52,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10,21]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/bmjopen-2025-103843"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-103843","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}